Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C14H17ClN2O.ClH |
Molecular Weight | 301.212 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.ClC1=CC=C(C=C1)C(=O)N[C@H]2CN3CCC2CC3
InChI
InChIKey=HSEQUIRZHDYOIX-ZOWNYOTGSA-N
InChI=1S/C14H17ClN2O.ClH/c15-12-3-1-11(2-4-12)14(18)16-13-9-17-7-5-10(13)6-8-17;/h1-4,10,13H,5-9H2,(H,16,18);1H/t13-;/m0./s1
Molecular Formula | C14H17ClN2O |
Molecular Weight | 264.751 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/20630711 | https://www.ncbi.nlm.nih.gov/pubmed/15523001Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/27729414
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20630711 | https://www.ncbi.nlm.nih.gov/pubmed/15523001
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/27729414
PNU-282987 is a potent and selective a7 nAChR agonist. This compound showed high affinity for the rat a7 nAChR (Ki = 26 nM) and activity at the a7–5-HT3 chimera (EC50 = 128 nM). In addition, PNU-282987 was found to be inactive at all tested monoamine, muscarine, glutamate, and GABA receptors at 1 uM concentration, except 5-HT3 receptors (Ki = 930 nM). The highly selective and potent a7 nAChR agonist PNU-282987 enhances GABAergic synaptic activity in the hippocampus in vitro, and reverses amphetamine induced auditory gating deficit in anesthetized rats. In addition, PNU-282987 improves the inherent gating deficit observed in a subset of rats and enhances amphetamine induced hippocampal activity. These results support the concept that a7 nAChR agonists represent a novel, potential pharmacotherapy in treatment of schizophrenia. It also has being shown that acute lung injury is reduced by PNU-282987 through changes in the macrophage profile.
CNS Activity
Originator
Sources: http://adisinsight.springer.com/drugs/800018656
Curator's Comment: # Pfizer
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Alpha7 nicotinic acetylcholine receptor activation ameliorates scopolamine-induced behavioural changes in a modified continuous Y-maze task in mice. | 2009 Jan 5 |
|
Human platelets express functional alpha7-nicotinic acetylcholine receptors. | 2011 Apr |
|
Neurotoxicity induced by okadaic acid in the human neuroblastoma SH-SY5Y line can be differentially prevented by α7 and β2* nicotinic stimulation. | 2011 Sep |
|
Interaction of bispyridinium compounds with the orthosteric binding site of human α7 and Torpedo californica nicotinic acetylcholine receptors (nAChRs). | 2011 Sep 25 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26239818
Curator's Comment: Can also be used i.p. (0.3mg/kg and 1.0mg/kg) https://www.ncbi.nlm.nih.gov/pubmed/24833065
or s.c. (10mg/kg)
https://www.ncbi.nlm.nih.gov/pubmed/20630711
Rats: eye drops of PNU-282987 resulted in neuroprotection against etinal ganglion cells (RGCs) loss in a dose-dependent manner using concentrations between 100 uM and 2 mM PNU-282987
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20875851
PNU-282987 (1, 3, and 10 uM) incubated for 16 h after
the 8-h rot/oligo period in SH-SY5Y cells produced a concentration-dependent protective effect; the maximum protective effect was achieved with 10 uM PNU282987 (50% neuroprotection)
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:53:32 GMT 2023
by
admin
on
Sat Dec 16 09:53:32 GMT 2023
|
Record UNII |
810P1694K2
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
810P1694K2
Created by
admin on Sat Dec 16 09:53:32 GMT 2023 , Edited by admin on Sat Dec 16 09:53:32 GMT 2023
|
PRIMARY | |||
|
PNU-282,987
Created by
admin on Sat Dec 16 09:53:32 GMT 2023 , Edited by admin on Sat Dec 16 09:53:32 GMT 2023
|
PRIMARY | |||
|
DTXSID801017103
Created by
admin on Sat Dec 16 09:53:32 GMT 2023 , Edited by admin on Sat Dec 16 09:53:32 GMT 2023
|
PRIMARY | |||
|
11243536
Created by
admin on Sat Dec 16 09:53:32 GMT 2023 , Edited by admin on Sat Dec 16 09:53:32 GMT 2023
|
PRIMARY | |||
|
123464-89-1
Created by
admin on Sat Dec 16 09:53:32 GMT 2023 , Edited by admin on Sat Dec 16 09:53:32 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SOLVATE->ANHYDROUS |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |